John Cameron speaks at DCAT Week about the 2024 threefold objectives of our Injectables Platform at our sterile injectable Drug Product facility CordenPharma Caponago (IT):
Firstly, the completion of our new GMP Lipid NanoParticle (LNP) clinical & commercial manufacturing area, which complements our already existing R&D LNP development area, as well as the capacity for producing peptide / polymer and other nanoparticles. As a CDMO, we are proud to be on the cutting edge of this exciting, rapidly growing area of the hashtag#pharma & biotech industry.
Secondly, we gained approval for a third high-speed commercial fill-finish line, which uses isolator technology and provides an additional 30 M injectable units per year.
Lastly, we have expanded our packaging area, which includes 2,200 square meters next door to the warehouse incorporating 4 high-speed and 2 semi-automated packaging lines, all with full serialization and aggregation.